Even though repurposed drugs are relatively common, and there are even successful examples in the literature, such as the use of sodium-glucose transport protein-2 (SGLT2) inhibitors that were firstly developed for diabetes mellitus [109], but also showed benefit in patients with heart failure chronic kidney disease [110,111], its success is limited [14,112]. The gene discussed is SLC5A2; the disease is chronic kidney disease.